Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Monoclonal Antibodies Produced for Alzheimer's Disease Blood Test

By LabMedica International staff writers
Posted on 09 Mar 2011
Monoclonal antibodies (mAbs) were successfully produced for a diagnostic blood test for Alzheimer's disease (AD).

A simple, easy to use diagnostic blood test for AD is ready for clinical testing. More...
Human sample testing has begun and will run over the next few months.

biOasis Technologies Inc. (Vancouver, BC, Canada) announced the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its Cognitest blood test for Alzheimer's disease. Working in collaboration with Fleet Bioprocessing (Hartley Witney, United Kingdom), and OxFabs (Oxford, United Kingdom), the company generated numerous antibodies and assessed their performance in prototype assays. The best performing mAbs were selected for use within production prototypes.

"The selection of monoclonal antibodies is an important step in the Cognitest program," said Rob Hutchison, biOasis Chairman and CEO. "Our strategy is to create new intellectual property and ensure ownership of key components within our products. We are now working to assess Cognitest using human samples from North America and Europe. Our intention is to expand the validation studies by collaborating with clinical thought leaders interested in an easy-to-use quantitative test for Alzheimer's disease. The ability to diagnose Alzheimer's has always been known to be very difficult due to the fact that many forms of dementia mimic Alzheimer's and as such a simple quick blood test would provide physicians with a tool to combat this dreadful disease."

Current initiatives within the Cognitest program include product and method development, validation using human samples, and regulatory approval in Europe. To enable faster adoption and greater use of Cognitest the company intends to out-license it to leading in vitro diagnostic companies.

In addition, biOasis is developing a proprietary carrier for the transport of therapeutic and imaging agents across the blood brain barrier--the Transcend program. Current initiatives within the Transcend program include production of materials for preclinical studies and conjugation to a range of small molecule and biologic therapeutics. To address the clinical need to transport drugs across the blood-brain barrier biOasis intends to license multiple candidate compounds from the Transcend program to corporate partners.

Related Links:

biOasis Technologies Inc.
Fleet Bioprocessing
OxFabs



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gastrointestinal Panel
Xpert® GI Panel
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.